Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

- 15 February 2023 - 1 mins read

             
Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

Related stories
31 May 2023 1 mins read

Collette : trouver une communauté à travers la CBP
31 May 2023 1 mins read

Diana : surmonter la spasticité avec sérénité  
31 May 2023 1 mins read

Diana: Taking spasticity in stride   
See more stories

Related Press Releases

20 June 2023

IPSEN – Buy-back programme – Art 5 of MAR –...
16 June 2023

Ipsen delivered sales growth and margin expansion in 2020 –...
16 June 2023

Ipsen delivers strong sales growth for the first nine months...
14 June 2023

Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental...
14 June 2023

Ipsen announces U.S. FDA submission acceptance of its supplemental New...
13 June 2023

U.S. FDA approves Bylvay® for patients living with cholestatic pruritus...
13 June 2023

IPSEN – Buy-back programme – Art 5 of MAR –...
12 June 2023

Ipsen to present new data on clinical outcomes and patient...
12 June 2023

Ipsen to present new data on clinical outcomes and patient...
12 June 2023

Ipsen to present new data on clinical outcomes and patient...